{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
National Research Corp.
National Research Corp. Experiences Valuation Adjustment Amidst Market Performance Challenges
National Research Corp. has recently adjusted its valuation, with its stock price at $11.61. Over the past year, the company has seen a notable decline in performance, contrasting with the S&P 500. Key financial metrics indicate a strong position relative to peers, despite recent challenges in the market.
Is National Research Corp. overvalued or undervalued?
As of October 17, 2025, National Research Corp. is considered overvalued with a shift to an expensive valuation grade, indicated by a P/E ratio of 17 and a Price to Book Value of 14.27, making it less attractive compared to its peers like Psychemedics Corp. with a P/E ratio of -8.09, despite its strong ROE and ROCE.
Is National Research Corp. overvalued or undervalued?
As of October 17, 2025, National Research Corp. is considered overvalued with a valuation grade of "expensive," reflected by its high P/E ratio of 17 and underperformance against the S&P 500, indicating that investors may be paying too much relative to its earnings and assets.
Is National Research Corp. technically bullish or bearish?
As of September 8, 2025, National Research Corp. shows a neutral trend with mixed signals, as weekly indicators are mildly bullish while daily indicators are mildly bearish, and the stock has underperformed the S&P 500 with a year-to-date return of -9.92%.
Is National Research Corp. overvalued or undervalued?
As of September 8, 2025, National Research Corp. is considered very expensive and overvalued, with a P/E ratio of 17 compared to its peer Psychemedics Corp. at 24.89, an EV to EBITDA ratio of 11.75, a Price to Book Value of 14.27, and significantly underperforming the S&P 500 with a year-to-date return of -9.92% and a five-year return of -68.24%.
Is National Research Corp. overvalued or undervalued?
As of June 10, 2025, National Research Corp. is considered very expensive with a P/E ratio of 17, significantly higher than its peer Psychemedics Corp. at -8.20, and despite a high ROE of 82.18%, its stock has underperformed with a 1-year return of -32.99% compared to the S&P 500's 10.26%, indicating it is overvalued relative to its peers and the market.
Is National Research Corp. technically bullish or bearish?
As of May 7, 2025, National Research Corp. shows a mildly bearish trend due to daily moving averages indicating bearish sentiment, while weekly indicators present mixed signals, suggesting a lack of strong momentum.
Who are in the management team of National Research Corp.?
As of March 2022, the management team of National Research Corp. includes Mr. Michael Hays as President and CEO, with Mr. John Nunnelly as Lead Independent Director, and Dr. Donald Berwick and Ms. JoAnn Martin as Independent Directors.
What does National Research Corp. do?
National Research Corporation (NRC Health) provides analytics and insights for healthcare providers and payers, with a market cap of $472.86 million. As of March 2025, it reported net sales of $34 million and a net profit of $6 million.
How big is National Research Corp.?
As of Jun 18, National Research Corp. has a market capitalization of 472.86 million and reported net sales of 141.30 million and net profit of 24.21 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
